Circulation最新文献

{"title":"Induced Cytokinesis Generates Highly Proliferative Mononuclear Cardiomyocytes at the Expense of Contractility.","authors":"Nicholas T Lam, Ngoc Uyen Nhi Nguyen, Waleed M Elhelaly, Ching-Cheng Hsu, Ivan Menendez-Montes, Feng Xiao, Shah R Ali, Nelson Vo, Nathan Briard, Lobna El-Feky, Qamar M Omari, Alisson C Cardoso, Yan Liu, Mahmoud Salama Ahmed, Shujuan Li, Suwannee Thet, Chao Xing, Lior Zangi, Hesham A Sadek","doi":"10.1161/CIRCULATIONAHA.124.065763","DOIUrl":"10.1161/CIRCULATIONAHA.124.065763","url":null,"abstract":"<p><strong>Background: </strong>Cytokinesis is the last step in the eukaryotic cell cycle, which physically separates a mitotic cell into 2 daughter cells. A few days after birth in mouse cardiomyocytes, DNA synthesis occurs without cytokinesis, leading to the majority of cardiomyocytes becoming binucleated instead of generating 2 daughter cells with 1 nucleus each. This results in cell cycle arrest of cardiomyocytes, and the mouse heart is no longer able to regenerate. A longstanding unanswered question is whether binucleation of cardiomyocytes is a result of cytokinesis failure.</p><p><strong>Methods: </strong>To address this, we generated several transgenic mouse models to determine whether forced induction of cardiomyocyte cytokinesis generates mononucleated cardiomyocytes and restores the endogenous regenerative properties of the myocardium. We focused on 2 complementary regulators of cytokinesis: Plk1 (polo-like kinase 1) and Ect2 (epithelial cell-transformation sequence 2).</p><p><strong>Results: </strong>We found that cardiomyocyte-specific transgenic overexpression of constitutively active Plk1(T210D) promotes mitosis and cytokinesis in adult hearts, whereas overexpression of Ect2 alone promotes only cytokinesis. Cardiomyocyte-specific overexpression of both Plk1(T210D) and Ect2 concomitantly (double transgenic) prevents binucleation of cardiomyocytes postnatally and results in widespread cardiomyocyte mitosis, cardiac enlargement, contractile failure, and death before 2 weeks of age. In contrast, doxycycline-inducible cardiomyocyte-specific overexpression of both genes (inducible double transgenic) in the adult heart results in cardiomyocyte mitosis and transient contractile dysfunction. Importantly, this transient induction of cytokinesis in adult mice improves left ventricular systolic function after myocardial infarction.</p><p><strong>Conclusions: </strong>These results collectively demonstrate that cytokinesis failure mediates cardiomyocyte multinucleation and cell cycle exit of postnatal cardiomyocytes, but may be a protective mechanism to preserve the contractile function of the myocardium.</p>","PeriodicalId":10331,"journal":{"name":"Circulation","volume":" ","pages":"1009-1023"},"PeriodicalIF":35.5,"publicationDate":"2025-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143254301","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evidence-Based Application of Natriuretic Peptides in the Evaluation of Chronic Heart Failure With Preserved Ejection Fraction in the Ambulatory Outpatient Setting.","authors":"Yogesh N V Reddy, Atsushi Tada, Masaru Obokata, Rickey E Carter, David M Kaye, M Louis Handoko, Mads J Andersen, Kavita Sharma, Ryan J Tedford, Margaret M Redfield, Barry A Borlaug","doi":"10.1161/CIRCULATIONAHA.124.072156","DOIUrl":"10.1161/CIRCULATIONAHA.124.072156","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Background: &lt;/strong&gt;Plasma NT-proBNP (N-terminal pro-B-type natriuretic peptide) is commonly used to diagnose heart failure with preserved ejection fraction (HFpEF), but its diagnostic performance in the ambulatory/outpatient setting is unknown because previous studies lacked objective reference standards.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;Among patients with chronic dyspnea, diagnosis of HFpEF or noncardiac dyspnea was determined conclusively by exercise catheterization in a derivation cohort (n=414), multicenter validation cohort 1 (n=560), validation cohort 2 (n=207), and a nonobese Japanese validation cohort 3 (n=77). Optimal NT-proBNP cut points for HFpEF rule out (optimizing sensitivity) and rule in (optimizing specificity) were derived and tested, stratified by obesity and atrial fibrillation. Derived cut points were tested in 3 additional validation cohorts (cohorts 4-6) in whom HFpEF was diagnosed by resting catheterization only (n=260), previous hospitalization for heart failure (n=447), or exercise echocardiography (n=517), respectively.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;Current recommended rule-out NT-proBNP threshold &lt;125 pg/mL had 82% sensitivity (95% CI, 77%-88%) with a body mass index (BMI) &lt;35 kg/m&lt;sup&gt;2&lt;/sup&gt;, decreasing to 67% (95% CI, 58%-77%) with a BMI ≥35 kg/m&lt;sup&gt;2&lt;/sup&gt;. A lower rule-out NT-proBNP threshold &lt;50 pg/mL displayed good sensitivity with a BMI &lt;35 kg/m&lt;sup&gt;2&lt;/sup&gt; (97% [95% CI, 95%-99%]), with a modest decline in sensitivity with a BMI ≥35 kg/m&lt;sup&gt;2&lt;/sup&gt; (86% [95% CI, 79%-93%]); diagnostic thresholds were confirmed in validation cohorts 1 and 2 (91% [95% CI, 88%-95%] and 86% [95% CI, 80%-93%] with a BMI &lt;35 kg/m&lt;sup&gt;2&lt;/sup&gt;; 80% [95% CI, 74%-87%] and 84% [95% CI, 74%-93%] with a BMI ≥35 kg/m&lt;sup&gt;2&lt;/sup&gt;). Current consensus age- and BMI-stratified rule-in thresholds demonstrated only 65% specificity (95% CI, 57%-72%). Rule-in NT-proBNP threshold ≥500 pg/mL had 85% specificity (95% CI, 78%-91%) with a BMI &lt;35 kg/m&lt;sup&gt;2&lt;/sup&gt; (87% [95% CI, 80%-94%] and 90% [95% CI, 81%-99%] in validation cohorts), with 100% specificity at a BMI ≥35 kg/m&lt;sup&gt;2&lt;/sup&gt; (93% [95% CI, 81%-100%] and 100% in validation cohorts). With a BMI ≥35 kg/m&lt;sup&gt;2&lt;/sup&gt;, lower rule-in thresholds (≥220 pg/mL) provided good specificity (88% [95% CI, 73%-100%]; 93% [95% CI, 81%-100%] and 100% in validation cohorts). Findings were consistent in validation cohorts 3 through 6 (sensitivity of &lt;50 pg/mL, 93%-98%; specificity of ≥500 pg/mL, 82%-89%). NT-proBNP provided no incremental discrimination among patients with history of AF; ≥98% of patients with AF and dyspnea were found to have HFpEF in our cohorts.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusions: &lt;/strong&gt;In patients with chronic unexplained dyspnea, current rule-in and rule-out NT-proBNP diagnostic thresholds lead to unacceptably high error rates, with important interactions by obesity and AF status. In our study, NT-proBNP provided little value in those with AF and dyspnea because the presence of AF is b","PeriodicalId":10331,"journal":{"name":"Circulation","volume":" ","pages":"976-989"},"PeriodicalIF":35.5,"publicationDate":"2025-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143001270","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Differential Associations of Cigar, Pipe, and Smokeless Tobacco Use Versus Combustible Cigarette Use With Subclinical Markers of Inflammation, Thrombosis, and Atherosclerosis: The Cross-Cohort Collaboration-Tobacco Working Group.","authors":"Zhiqi Yao, Erfan Tasdighi, Zeina A Dardari, Kunal K Jha, Ngozi Osuji, Tanuja Rajan, Ellen Boakye, Carlos J Rodriguez, Kunihiro Matsushita, Eleanor M Simonsick, Joao A C Lima, Rachel Widome, Debbie L Cohen, Lawrence J Appel, Amit Khera, Michael E Hall, Suzanne Judd, Shelley A Cole, Ramachandran S Vasan, Emelia J Benjamin, Aruni Bhatnagar, Andrew P DeFilippis, Michael J Blaha","doi":"10.1161/CIRCULATIONAHA.124.070852","DOIUrl":"10.1161/CIRCULATIONAHA.124.070852","url":null,"abstract":"<p><strong>Background: </strong>Understanding the associations of tobacco product use with subclinical markers is essential in evaluating health effects to inform regulatory policy. This is particularly relevant for noncigarette products (eg, cigars, pipes, and smokeless tobacco), which have been understudied because of their low prevalence in individual cohorts.</p><p><strong>Methods: </strong>This cross-sectional study included 98 450 participants from the Cross-Cohort Collaboration-Tobacco data set. Associations between the use of tobacco products and subclinical markers (high-sensitivity C-reactive protein, interleukin-6, fibrinogen, D-dimer, coronary artery calcium, carotid intima-media thickness, carotid plaque, and ankle-brachial index) were evaluated. The analyses used multivariable linear and logistic regression models to examine current use status for each product, with additional analyses of \"sole\" and \"exclusive\" noncigarette use (versus never use of either cigarettes or specific noncigarette tobacco). Sole use was defined as the current use of a given noncigarette tobacco without concurrent combustible cigarette use, whereas exclusive use was defined as current noncigarette tobacco use without any history of combustible cigarette use.</p><p><strong>Results: </strong>A total of 20.0%, 3.0%, 0.8%, and 1.5% of participants were current cigarette, cigar, pipe, or smokeless tobacco users, respectively. Current cigarette use was linked to higher levels of all markers compared with never cigarette use. Compared with respective reference groups, current, sole, and exclusive cigar use was associated with 10% (95% CI, 1-20), 19% (95% CI, 12-26), and 11% (95% CI, 2-21) higher high-sensitivity C-reactive protein levels on the geometric mean scale. Similar associations were noted for pipe and smokeless tobacco use. For interleukin-6, we observed that sole cigar use was associated with a 15% (95% CI, 6-24) higher level, whereas current, sole, and exclusive pipe use were associated with 22% to 32% (all <i>P</i> values <0.05) higher levels compared with their respective reference groups. Fibrinogen levels were 2% to 6% higher (all <i>P</i> values <0.05) among sole users of cigars, pipes, and smokeless tobacco, compared with their respective reference groups. Additionally, noncigarette tobacco use was moderately associated with carotid plaque and carotid intima-media thickness.</p><p><strong>Conclusions: </strong>Use of noncigarette tobacco products is linked to subclinical markers related to cardiovascular harm. Inflammatory markers, such as high-sensitivity C-reactive protein and interleukin-6, have the potential for assessing early cardiovascular harm from using these products and aiding regulatory authorities in evaluating their associated risks.</p>","PeriodicalId":10331,"journal":{"name":"Circulation","volume":" ","pages":"993-1005"},"PeriodicalIF":35.5,"publicationDate":"2025-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11975489/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143045695","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction to: Targeting NPM1 Epigenetically Promotes Postinfarction Cardiac Repair by Reprogramming Reparative Macrophage Metabolism.","authors":"Sheng Zhang, Yunkai Zhang, Xuewen Duan, Bo Wang, Zhenzhen Zhan","doi":"10.1161/CIR.0000000000001332","DOIUrl":"https://doi.org/10.1161/CIR.0000000000001332","url":null,"abstract":"","PeriodicalId":10331,"journal":{"name":"Circulation","volume":"151 14","pages":"e920"},"PeriodicalIF":35.5,"publicationDate":"2025-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143802754","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"<i>Circulation</i> Global Rounds: Denmark.","authors":"Caroline Espersen, Anne Marie Reimer Jensen, Tor Biering-Sørensen","doi":"10.1161/CIRCULATIONAHA.124.071545","DOIUrl":"https://doi.org/10.1161/CIRCULATIONAHA.124.071545","url":null,"abstract":"","PeriodicalId":10331,"journal":{"name":"Circulation","volume":"151 14","pages":"973-975"},"PeriodicalIF":35.5,"publicationDate":"2025-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143802668","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Direct-to-Consumer Genetic Testing for Cardiovascular Disease: A Scientific Statement From the American Heart Association.","authors":"Leland E Hull, Aaron W Aday, Quan M Bui, Jasmine A Luzum, James M Muchira, Hannah Wand, C Anwar A Chahal, Mina K Chung, Anne E Kwitek, Silvana Molossi, Pradeep Natarajan","doi":"10.1161/CIR.0000000000001304","DOIUrl":"10.1161/CIR.0000000000001304","url":null,"abstract":"<p><p>Despite insufficient evidence to support direct-to-consumer genetic testing in routine clinical care, cardiovascular clinicians increasingly face questions about its utility and interpretation because individuals can purchase these tests directly from laboratories. A burgeoning marketplace offers an expanding array of testing options. In many cases, direct-to-consumer genetic testing advertises information that could inform one's risk of heritable disease, including insight into having a genetic predisposition to cardiovascular disease or data about gene-drug interactions that could affect response to cardiovascular medications. Navigating clinical questions about direct-to-consumer genetic testing involves understanding the evolution and oversight of the marketplace; the scope of direct-to-consumer genetic testing offerings; and the risks, benefits, and limitations of said testing. In this American Heart Association scientific statement, we summarize the state of the direct-to-consumer genetic testing industry, review types of cardiovascular genetic information that may be included in direct-to-consumer genetic testing, describe approaches to evaluate test quality, and provide resources for clinicians navigating questions about direct-to-consumer genetic testing. If direct-to-consumer genetic test information is used in clinical care, care should be taken to assess the limitations of the test, to contextualize the information specifically to the patient, and to corroborate potentially actionable monogenic findings.</p>","PeriodicalId":10331,"journal":{"name":"Circulation","volume":" ","pages":"e905-e917"},"PeriodicalIF":35.5,"publicationDate":"2025-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143613761","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction to: 2024 ACC/AHA/AACVPR/APMA/ABC/SCAI/SVM/SVN/SVS/SIR/VESS Guideline for the Management of Lower Extremity Peripheral Artery Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.","authors":"Heather L Gornik, Herbert D Aronow, Philip P Goodney, Shipra Arya, Luke Packard Brewster, Lori Byrd, Venita Chandra, Douglas E Drachman, Jennifer M Eaves, Jonathan K Ehrman, John N Evans, Thomas S D Getchius, J Antonio Gutiérrez, Beau M Hawkins, Connie N Hess, Karen J Ho, W Schuyler Jones, Esther S H Kim, Scott Kinlay, Lee Kirksey, Debra Kohlman-Trigoboff, Chandler A Long, Amy West Pollak, Saher S Sabri, Lawrence B Sadwin, Eric A Secemsky, Maya Serhal, Mehdi H Shishehbor, Diane Treat-Jacobson, Luke R Wilkins","doi":"10.1161/CIR.0000000000001329","DOIUrl":"https://doi.org/10.1161/CIR.0000000000001329","url":null,"abstract":"","PeriodicalId":10331,"journal":{"name":"Circulation","volume":"151 14","pages":"e918"},"PeriodicalIF":35.5,"publicationDate":"2025-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143802686","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Natriuretic Peptides for the Diagnosis of Heart Failure With Preserved Ejection Fraction.","authors":"Torbjørn Omland, Nicholas L Mills","doi":"10.1161/CIRCULATIONAHA.125.073788","DOIUrl":"https://doi.org/10.1161/CIRCULATIONAHA.125.073788","url":null,"abstract":"","PeriodicalId":10331,"journal":{"name":"Circulation","volume":"151 14","pages":"990-992"},"PeriodicalIF":35.5,"publicationDate":"2025-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143802755","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Nrf3-Mediated Mitochondrial Superoxide Promotes Cardiomyocyte Apoptosis and Impairs Cardiac Functions by Suppressing Pitx2.","authors":"Qishan Chen, Ancheng Zheng, Xiaolei Xu, Zhenning Shi, Mei Yang, Shasha Sun, Leyu Wang, Yumeng Wang, Haige Zhao, Qingzhong Xiao, Li Zhang","doi":"10.1161/CIRCULATIONAHA.124.070286","DOIUrl":"10.1161/CIRCULATIONAHA.124.070286","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Background: &lt;/strong&gt;Myocardial infarction (MI) elicits mitochondria reactive oxygen species (ROS) production and cardiomyocyte (CM) apoptosis. Nrf3 (nuclear factor erythroid 2-related factor 3) has an established role in regulating redox signaling and tissue homeostasis. Here, we aimed to evaluate the role and mechanism of Nrf3 in injury-induced pathological cardiac remodeling.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;Global (Nrf3-KO) and CM-specific (Nrf3&lt;sup&gt;△CM&lt;/sup&gt;) Nrf3 knockout mice were subjected to MI or ischemia/reperfusion injury, followed by functional and histopathological analysis. Primary neonatal mouse and rat ventricular myocytes and CMs derived from human induced pluripotent stem cells were used to evaluate the impact of Nrf3 on CM apoptosis and mitochondrial ROS production. Chromatin immunoprecipitation sequencing and immunoprecipitation-mass spectrometry analysis were used to uncover potential targets of Nrf3. MitoParaquat administration and CM-specific adeno-associated virus vectors were used to further confirm the &lt;i&gt;i&lt;/i&gt;n vivo relevance of the identified signal pathways.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;Nrf3 was expressed mainly in CMs in healthy human hearts, and an increased level of Nrf3 was observed in CMs within the border zone of infarcted human hearts and murine cardiac tissues after MI. Both global and CM-specific Nrf3 knockout significantly decreased injury-induced mitochondrial ROS production, CM apoptosis, and pathological cardiac remodeling, consequently improving cardiac functions. In addition, cardiac-specific Nrf3 overexpression reversed the ameliorative cardiac phenotypes observed in Nrf3-KO mice. Functional studies showed that Nrf3 promoted neonatal mouse ventricular myocyte, neonatal rat ventricular myocyte, and CMs derived from human induced pluripotent stem cell apoptosis by increasing mitochondrial ROS production. Critically, augmenting mitochondrial ROS with MitoParaquat blunted the beneficial effects of Nrf3 deletion on cardiac function and remodeling. Mechanistically, a redox regulator Pitx2 (paired-like homeodomain transcription factor 2) was identified as one of the main target genes of Nrf3. Specifically, Nrf3 binds to &lt;i&gt;Pitx2&lt;/i&gt; promoter, where it increases DNA methylation through recruiting heterogeneous nuclear ribonucleoprotein K and DNA-methyltransferase 1 complex, thereby inhibiting Pitx2 expression. CM-specific knockdown of Pitx2 blunted the beneficial effects of Nrf3 deletion on cardiac function and remodeling, and cardiac-specific Pitx2 overexpression attenuated MI-induced mitochondrial ROS production and CM apoptosis, as well as preserved cardiac functions after MI.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusions: &lt;/strong&gt;Nrf3 promotes injury-induced CM apoptosis and deteriorates cardiac functions by increasing mitochondrial ROS production through suppressing Pitx2 expression. Targeting the Nrf3-Pitx2-mitochondrial ROS signal axis may therefore represent a novel therapeutic approach for MI treatment.&lt;/p","PeriodicalId":10331,"journal":{"name":"Circulation","volume":" ","pages":"1024-1046"},"PeriodicalIF":35.5,"publicationDate":"2025-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143647524","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sex Differences in Peripheral Vascular Disease: A Scientific Statement From the American Heart Association.","authors":"Esther S H Kim, Shipra Arya, Yolanda Bryce, Heather L Gornik, Chandler A Long, Mary M McDermott, Amy West Pollak, Vincent Lopez Rowe, Alexander E Sullivan, Mary O Whipple","doi":"10.1161/CIR.0000000000001310","DOIUrl":"10.1161/CIR.0000000000001310","url":null,"abstract":"<p><p>Sex differences in the risk factors, diagnosis, treatment, and outcomes of patients with cardiovascular disease have been well described; however, the bulk of the literature has focused on heart disease in women. Data on sex differences in peripheral vascular disease are ill defined, and there is a need to report and understand those sex-related differences to mitigate adverse outcomes related to those disparities. Although peripheral vascular disease is a highly diverse group of disorders affecting the arteries, veins, and lymphatics, this scientific statement focuses on disorders affecting the peripheral arteries to include the aorta and its branch vessels. The purpose of this scientific statement is to report the current status of sex-based differences and disparities in peripheral vascular disease and to provide research priorities to achieve health equity for women with peripheral vascular disease.</p>","PeriodicalId":10331,"journal":{"name":"Circulation","volume":" ","pages":"e877-e904"},"PeriodicalIF":35.5,"publicationDate":"2025-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143596447","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}